Supporting Information

Structure-activity relationships for CYP4B1 bioactivation of 4-ipomeanol congeners: Direct correlation between cytotoxicity and trapped reactive intermediates

John P. Kowalski,[†] Matthew G. McDonald,[†] Dale Whittington,[†] Miklos Guttman,[†] Michele Scian,[†] Marco Girhard,[‡] Helmut Hanenberg,[§] Constanze Wiek[¶] and Allan E. Rettie^{†,*}

*Corresponding author

[†]Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, WA 98105, US [‡]Institute of Biochemistry, Heinrich-Heine University, 40225 Düsseldorf, Germany [§]Department of Pediatrics III, University Children's Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany [¶]Department of Otorhinolaryngology and Head/Neck Surgery, Heinrich-Heine University, 40225 Düsseldorf, Germany

ltem	Page
Fig. S1. Western blot assessment of CYP4B1 expression levels in HepG2 cells	S3
Fig. S2. MS/MS fragmentation data for C5-Adduct isomers 2 – 4	S4
Fig. S3. HSQC structural validation for synthesized C5-GSH/NAL isomer 1	S5
Fig. S4. ROESY characterization for synthesized C5-GSH/NAL isomer 1	S6
Fig. S5. C2-OH, C5-OH, C8-OH Metabolite identification	S7
Fig. S6. N-Alkyl-3-furancarboxamide stability assessment in tissue culture media	S8
Supplemental Methods: NMR Spectroscopy	S9
Fig. S7. ¹ H NMR: C1	S10
Fig. S8. ¹ H NMR: C2	S11
Fig. S9. ¹ H NMR: C3	S12
Fig. S10. ¹ H NMR: C4	S13
Fig. S11. ¹ H NMR: C5	S14
Fig. S12. ¹ H NMR: C6	S15
Fig. S13. ¹ H NMR: C7	S16
Fig. S14. ¹ H NMR: C8	S17
Fig. S15. ¹ H NMR: C2-OH	S18
Fig. S16. ¹ H NMR: C5-OH	S19
Fig. S17. ¹ H NMR: C8-OH	S20



Fig. S1. Cell lines were modified with lentivirus to over-express CYP4B1 and control vector. HepG2-CYP4B1 cells showed ~130 pmol CYP4B1/mg total protein in lysates, migrating at ~55 kDa, as quantified using the recombinantly expressed and purified enzyme as standards. CYP4B1 was not detected in the control vector cell line. B-Actin was used as loading control to ensure equal protein was loaded for both cell lines into the gel.

(A) C5-Adduct isomer 2 MS/MS



(C) C5-Adduct isomer 4 MS/MS



Fig. S2. MS/MS spectra were analyzed for the adducts generated by C5 incubation with CYP4B1 in the presence of GSH and NAL; these suggested C5-Adduct isomers of each other were not definitively characterized by NMR techniques. Isomer 2 (A) eluted at 40.8 min and isomer 4 (C) eluted at 42.4 min, both showed the accurate parent m/z 657.29 for the trapped pyrrole species and the characteristic fragmentation of GSH adducts of [M+H - 129] (m/z 528) and [M+H - 75] (m/z 582). Isomer 3 (B), eluted at 41.9 min, had the accurate parent m/z 657.29, and the GSH fragmentation corresponding to [M+H - 129] (m/z 528), but did not show the species for [M+H - 75](m/z 582). Therefore, it was postulated that isomer 3 could be a cyclized variant that results from first GSH 1,4-addition to the reactive ene-dial of bioactivated C5, followed by NAL addition and then the free acid of the GSH-glycine moiety attacking an iminium intermediate resulting in a cyclic adduct. A possible structure and mechanism, along with assigned fragmentation data, is provided (**D**).

(B) C5-Adduct isomer 3 MS/MS



(D) Proposed mechanism, structure, and fragmentation for C5-Adduct isomer 3





Fig. S3. Structural validation for **C5-GSH/NAL** isomer 1 (synthesized) was performed *via* multiplicity-edited Heteronuclear Single Quantum Correlation (HSQC) NMR (methanol-d4 solvent). The annotated spectra show CH and CH₃ groups denoted by red and CH₂ groups denoted by blue. Chemical shifts have also been provided.



Fig. S4. 2D Rotating-frame Overhauser Effect SpectroscopY (ROESY) (D₂O solvent) was used to characterize the thiol attachment site to the pyrrole adduct from through-space proton interactions for **C5-GSH/NAL** isomer 1 (synthesized). The pyrrole proton (8H) showed proximity to the NAL protons (9H, 10H, 11H) as well as the other pyrrole proton (7H), denoted by double-ended arrows C, B, A, and G, respectively. Conversely, pyrrole proton (7H) lacked interaction with NAL aliphatic chain protons but showed clear proximity with GSH protons (6_aH, 6_bH, 2H, 1H) denoted by double-ended arrows D, E, and F, respectively. Lastly, the GSH proton (6_aH) shows interaction with the NAL proton (9H); the lack of GSH proton (6_bH) interaction with NAL proton (9H) may be attributed to a shielding effect from the GSH Sulfur. These assignments specified the pyrrole protons (7H, 8H) as straddling the carboxamide with the GSH moiety attached adjacent to the NAL side chain.



Fig. S5. C2-, C5-, C8-OH Metabolite identification. Upper panels A, C, and E are the synthetic standards for C2-OH, C5-OH, and C8-OH, respectively. The extracted ion chromatogram (XIC) windows (in daltons) are provided above the chemical structures. Lower panels B, D, and F show the metabolic products generated by CYP4B1 from C2, C5, and C8 with matching retention times for C2-OH, C5-OH, and C8-OH, respectively, and used the same XIC window. Minor products which may correspond to internal hydroxylation metabolites of the same mass were observed for both C5 and C8.



Fig. S6. *N*-Alkyl-3-furancarboxamide stability assessment in tissue culture media. Compounds **C2**, **C5**, **C8** and diltiazem (a compound with a labile acetate ester commonly used as a stability control in depletion experiments) were dosed to complete tissue culture media at 100 μ M. Samples were taken at times 0, 24, 48, and 72 hours and the % remaining compound was determined *via* LC-UV at 254 nm. No significant depletion of **C2**, **C5**, or **C8** was observed after 72 hours, while diltiazem, with a labile ester, dropped to ~35%. Data shown represents the mean ± SD, from three replicates.

Supplemental Methods: NMR Spectroscopy

All NMR experiments were performed at 25 °C on a 499.73 MHz Agilent DD2 spectrometer equipped with either a 5 mm triple-resonance ¹H(¹³C/¹⁵N), z-axis pulsedfield gradient probe head. For characterization and spectral assignment purposes, the samples were ~20 mM solutions in either CD₃OD (99.8% D, Cambridge Isotopes) or D₂O (99.9% D, Cambridge Isotopes). The spectra were referenced to residual solvent peaks at 4.8 (CD₃OD or D₂O). GSH/NAL proton resonances were assigned through a combination of two-dimensional (2D) ROESY and HSQC experiments. Homonuclear 2D experiments were acquired with 1024 complex data points in the t2 time domain (sw = 5000 Hz, d = 1.5 s) and 32 scans were averaged for each of the 400 increments in the t1 domain. The 2-D ROESY experiment was recorded in phase sensitive Hypercomplex 2D mode with States-TPPI in F1, and a 350 ms spinlock mixing sequence. Carbon resonances were assigned through two dimensional ¹H–¹³C HSQC, acquired at natural isotopic abundance with 1024 complex data points in the t2 time domain (sw = 5000 Hz, d1= 1 s) and 64 averaged accumulations for each of the 400 increments in the t1 domain. All two-dimensional spectra were acquired in phase-sensitive Hypercomplex 2D mode with States-TPPI for guadrature detection in F1. The NMR data were analyzed using MNova 14.0 processing software (Mestrelab Research, Santiago de Compostela, Spain).

Fig. S7. ¹H NMR (500 MHz, CDCl₃): *N*-Methyl-3-furancarboxamide (C1)





Fig. S8. ¹H NMR (500 MHz, CDCl₃): *N*-Ethyl-3-furancarboxamide (**C2**)



Fig. S9.¹H NMR (500 MHz, CDCl₃): *N*-Propyl-3-furancarboxamide (**C3**)



Fig. S10. ¹H NMR (500 MHz, CDCl₃): *N*-Butyl-3-furancarboxamide (C4)



Fig. S11.¹H NMR (500 MHz, CDCl₃): *N*-Pentyl-3-furancarboxamide (C5)



Fig. S12.¹H NMR (500 MHz, CDCl₃): *N*-Hexyl-3-furancarboxamide (C6)



















